Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 84

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 84
---
 Flows 

The following table summarizes our sources and uses of cash for each of the periods presented: 

Nine Months EndedSeptember 30,(in thousands)20252024Net change in cash, cash equivalents and restricted cash:Net cash used in operating activities$(125,308)$(139,110)Net cash (used in) provided by investing activities(137,093)20,204 Net cash provided by financing activities150,950 195,875 Net change in cash, cash equivalents, and restricted cash$(111,451)$76,969 

Operating Activities 

Net cash used in operating activities for the nine months ended September 30, 2025 was driven primarily by the following uses of cash:

•$155.1 million net loss;

•$3.7 million change in lease liabilities

•$3.6 million change in deferred revenue — related party; and

•$2.8 million change in accrued expenses and other current liabilities.

30

These were offset by:

•$36.3 million of non-cash amounts included in net loss, which primarily consisted of stock-based compensation expense, restricted stock issuance expense, non-cash lease expense, depreciation expense, and change in fair value of short-term investment — related party;

•$1.9 million change in prepaid and other current assets; and

•$1.6 million change in accounts payable.

Net cash used in operating activities for the nine months ended September 30, 2024 was driven primarily by the following uses of cash:

•$153.6 million net loss;

•$55.0 million change in collaboration receivable — related party;

•$13.5 million change in accrued settlement payment — related party;

•$9.5 million change in prepaid and other current assets;

•$7.7 million change in accounts payable; and

•$6.0 million change in lease liabilities.

These were offset by:

•$32.3 million of non-cash amounts included in net loss, which primarily consisted of stock-based compensation expense, non-cash lease expense, depreciation and amortization expense, and change in fair value of short-term investment — related party;

•$71.9 million change in deferred revenue from consideration received from BMS in September 2024; and

•$2.0 million change in accrued expenses and other current liabilities.

Investing Activities 

Net cash used in investing activities for the nine months ended September 30